GloboScience

GloboScience

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

GloboScience is a specialized regulatory consulting firm that leverages deep expertise and a proprietary network to navigate complex FDA and global health authority approvals. Founded in 2019, the company differentiates itself by claiming involvement with products comprising the ten fastest FDA approvals and a track record of over 2,000 therapeutic programs. It operates as a service provider to biotech and pharma companies, helping them transform scientific data into successful regulatory strategies to achieve first-cycle approvals and accelerate time-to-market.

Rare DiseasesOncology (via Immunotherapy)Various via broad expertise

Technology Platform

Proprietary regulatory strategy and intelligence framework (IDEAS: Insight, Direction, Experience, Advice, Strategies) leveraging a network of former regulators and industry experts, historical data from 2000+ programs, and experience with fastest-ever FDA approvals.

Opportunities

Significant growth driven by the increasing complexity of drug development, especially in cell/gene therapy and rare diseases where regulatory pathways are novel.
The surge in advanced therapeutic medicinal products (ATMPs) creates a sustained demand for consultancies that can navigate uncharted regulatory territory and secure accelerated approvals.

Risk Factors

High dependence on key personnel and reputation; loss of senior experts could cripple the business.
Intense competition from large CROs and other boutique regulatory consultancies.
Success is indirectly tied to client product outcomes, which are subject to scientific and clinical risk beyond regulatory control.

Competitive Landscape

Competes with large, full-service CROs (e.g., IQVIA, Parexel) that have regulatory divisions, as well as specialized boutique regulatory affairs consultancies. Differentiation is based on claimed elite expertise, a track record with ultra-fast approvals, and a focus on creating precedent-setting pathways rather than following standard processes.